$39.5 Million is the total value of Foresite Capital Management III, LLC's 4 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | New | Ascendis Pharma A/Ssponsored ads | $17,985,000 | – | 133,691 | +100.0% | 45.53% | – |
| NTRA | New | Natera, Inc. | $8,498,000 | – | 91,000 | +100.0% | 21.51% | – |
| VRNA | Verona Pharma PLC.sponsored ads | $7,467,000 | +22.6% | 1,111,112 | 0.0% | 18.90% | +123.9% | |
| CBAY | Cymabay Therapeutics, Inc. | $5,549,000 | -7.4% | 1,641,804 | 0.0% | 14.05% | +69.0% | |
| NVAX | Exit | Novavax, Inc. | $0 | – | -5,000 | -100.0% | -1.44% | – |
| EPZM | Exit | Epizyme, Inc. | $0 | – | -998,278 | -100.0% | -7.09% | – |
| XLRN | Exit | Acceleron Pharma Inc. | $0 | – | -108,630 | -100.0% | -25.92% | – |
| ACRS | Exit | Aclaris Therapeutics, Inc. | $0 | – | -1,954,904 | -100.0% | -48.80% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 24 | Q3 2021 | 17.6% |
| Acceleron Pharma Inc. | 22 | Q3 2021 | 25.9% |
| CymaBay Therapeutics, Inc. | 20 | Q3 2022 | 17.6% |
| Aerie Pharmaceuticals, Inc. | 18 | Q1 2020 | 33.5% |
| Ascendis Pharma A/S | 17 | Q3 2022 | 47.8% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 27.4% |
| Natera, Inc. | 16 | Q3 2022 | 21.5% |
| Aimmune Therapeutics, Inc. | 16 | Q3 2019 | 8.1% |
| Verona Pharma PLC. | 15 | Q3 2022 | 30.0% |
| WAVE Life Sciences Ltd. | 15 | Q2 2019 | 20.0% |
View Foresite Capital Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 4 | 2021-11-03 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 3 | 2021-02-10 |
View Foresite Capital Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.